Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

NCT06258668 · clinicaltrials.gov ↗

RECRUITING

Status

505

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-severe Plaque Psoriasis

Interventions

DRUG: Deucravacitinib

Sponsor

Bristol-Myers Squibb